药品通用名/英文 |
NDC号/批准号 |
商标名 |
成份名 |
剂型 |
公司/生产厂 |
上市国/产地 |
规格/包装规格 |
备注 |
操作 |
甲苯磺他拉唑帕利胶囊 |
0069-1195-30 |
Talzenna |
talazoparib |
capsule |
PFIZER LABORATORIES DIV PFIZER INC |
USA |
1 mg*30CAP/BOTTLE |
|
请先登录 |
甲苯磺他拉唑帕利胶囊 |
|
Talzenna |
talazoparib |
capsule |
Pfizer /Excella GmbH & Co. KG |
FRANCE/Germany |
0.25 mg*30CAP/BOTTLE |
|
请先登录 |
甲苯磺他拉唑帕利胶囊 |
|
Talzenna |
talazoparib |
capsule |
Pfizer /Excella GmbH & Co. KG |
FRANCE/Germany |
1 mg*30CAP/BOTTLE |
|
请先登录 |
甲苯磺他拉唑帕利胶囊 |
|
Talzenna |
talazoparib |
capsule |
Pfizer Pharma GmbH/Excella GmbH & Co. KG |
Germany |
0.25 mg*30CAP/BOTTLE |
|
请先登录 |
甲苯磺他拉唑帕利胶囊 |
|
Talzenna |
talazoparib |
capsule |
Pfizer Pharma GmbH/Excella GmbH & Co. KG |
Germany |
1 mg*30CAP/BOTTLE |
|
请先登录 |
甲苯磺他拉唑帕利胶囊 |
|
Talzenna |
talazoparib |
capsule |
Pfizer Limited/Excella GmbH&Co.KG |
UK/Germany |
0.25 mg*30CAP/BOTTLE |
|
请先登录 |
甲苯磺他拉唑帕利胶囊 |
|
Talzenna |
talazoparib |
capsule |
Pfizer Limited/Excella GmbH&Co.KG |
UK/Germany |
0.25 mg*30,60,,90cap/box |
|
请先登录 |
甲苯磺他拉唑帕利胶囊 |
|
Talzenna |
talazoparib |
capsule |
Pfizer Limited/Excella GmbH&Co.KG |
UK/Germany |
1mg*30CAP/BOTTLE |
|
请先登录 |
甲苯磺他拉唑帕利胶囊 |
|
Talzenna |
talazoparib |
capsule |
Pfizer Limited/Excella GmbH&Co.KG |
UK/Germany |
1 mg*30cap/box |
|
请先登录 |
硫酸拉罗替尼胶囊 |
71777-390-01 |
VITRAKVI |
larotrectinib |
capsule |
Loxo Oncology, Inc. |
USA |
25 mg*60 Capsules/BOTTLE |
|
请先登录 |
硫酸拉罗替尼胶囊 |
71777-391-01 |
VITRAKVI |
larotrectinib |
capsule |
Loxo Oncology, Inc. |
USA |
100 mg*60 Capsules/BOTTLE |
|
请先登录 |
硫酸拉罗替尼口服溶液 |
71777-392-01 |
VITRAKVI |
larotrectinib |
Oral Solution |
Loxo Oncology, Inc. |
USA |
20 mg/mL ,100 mL/BOTTLE |
|
请先登录 |
达可替尼片 |
0069-0197-30 |
Vizimpro |
dacomitinib |
tablet, |
PFIZER LABORATORIES DIV PFIZER INC |
USA |
15mg*30tablets/bottle |
|
请先登录 |
达可替尼片 |
0069-1198-30 |
Vizimpro |
dacomitinib |
tablet, |
PFIZER LABORATORIES DIV PFIZER INC |
USA |
30mg*30tablets/bottle |
|
请先登录 |
达可替尼片 |
0069-2299-30 |
Vizimpro |
dacomitinib |
tablet, |
PFIZER LABORATORIES DIV PFIZER INC |
USA |
45mg*30tablets/bottle |
|
请先登录 |
达可替尼片 |
|
Vizimpro |
dacomitinib |
tablet, |
ファイザー株式会社 |
JP |
15mg*30tablets/box |
|
请先登录 |
达可替尼片 |
|
Vizimpro |
dacomitinib |
tablet, |
ファイザー株式会社 |
JP |
45mg*30tablets/box |
|
请先登录 |
达可替尼片 |
|
Vizimpro |
dacomitinib |
tablet, |
Pfizer Limited/Pfizer Manufacturing Deutschland GmbH |
UK/Germany |
15mg*30tablets/bottle |
|
请先登录 |
达可替尼片 |
|
Vizimpro |
dacomitinib |
tablet, |
Pfizer Limited/Pfizer Manufacturing Deutschland GmbH |
UK/Germany |
30mg*30tablets/bottle |
|
请先登录 |
达可替尼片 |
|
Vizimpro |
dacomitinib |
tablet, |
Pfizer Limited/Pfizer Manufacturing Deutschland GmbH |
UK/Germany |
45mg*30tablets/bottle |
|
请先登录 |
达可替尼片 |
|
Vizimpro |
dacomitinib |
tablet, |
Pfizer S.r.l./Pfizer Manufacturing Deutschland GmbH |
Italia/Germany |
15mg*30tablets/bottle |
|
请先登录 |
达可替尼片 |
|
Vizimpro |
dacomitinib |
tablet, |
Pfizer S.r.l./Pfizer Manufacturing Deutschland GmbH |
Italia/Germany |
30mg*30tablets/bottle |
|
请先登录 |
达可替尼片 |
|
Vizimpro |
dacomitinib |
tablet, |
Pfizer S.r.l./Pfizer Manufacturing Deutschland GmbH |
Italia/Germany |
45mg*30tablets/bottle |
|
请先登录 |
达可替尼片 |
注册证号 H20190037 |
多泽润/VIZIMPRO |
dacomitinib |
tablet, |
Pfizer Limited/Pfizer Manufacturing Deutschland GmbH |
中国/德国 |
45mg/10片/盒,30片/盒。 |
|
请先登录 |
达可替尼片 |
注册证号 H20190036 |
多泽润/VIZIMPRO |
dacomitinib |
tablet |
Pfizer Limited/Pfizer Manufacturing Deutschland GmbH |
中国/德国 |
15mg/10片/盒,31片/盒。 |
|
请先登录 |
达可替尼片 |
HK-66413 |
Vizimpro |
dacomitinib |
tablet, |
PFIZER CORPORATION HONG KONG LIMITED |
HONG KONG |
15mg |
|
请先登录 |
达可替尼片 |
HK-66414 |
Vizimpro |
dacomitinib |
tablet, |
PFIZER CORPORATION HONG KONG LIMITED |
HONG KONG |
30mg |
|
请先登录 |
达可替尼片 |
HK-66415 |
Vizimpro |
dacomitinib |
tablet, |
PFIZER CORPORATION HONG KONG LIMITED |
HONG KONG |
45mg |
|
请先登录 |
注射剂用盐酸考泮利司 |
50419-385-01 |
Aliqopa |
copanlisib |
injection |
Bayer HealthCare Pharmaceuticals Inc. |
USA |
60 mg/4ml(15 mg/1 mL)/vial/box |
|
请先登录 |
注射剂用盐酸考泮利司 |
50419-385-72 |
Aliqopa |
copanlisib |
injection |
Bayer HealthCare Pharmaceuticals Inc. |
USA |
60 mg/4ml(15 mg/1 mL)/vial/box |
|
请先登录 |